DVS Sciences Introduces the CyTOF® 2 Mass Cytometer and New MaxPar® Panel Kits for Transformational High-Parameter Single Cell Analysis

Sat May 4, 2013 11:00am EDT

* Reuters is not responsible for the content in this press release.

DVS Sciences Introduces the CyTOF® 2 Mass Cytometer and New MaxPar® Panel Kits for Transformational High-Parameter Single Cell Analysis

DVS Sciences, Inc., a privately held innovator of novel multi-parameter single-cell analyzers and reagents for biological research, today announced the introduction of the new CyTOF 2 Mass Cytometer and new MaxPar Panel Kits designed specifically for simultaneous high-parameter single cell analysis.

The DVS Sciences® CyTOF 2 system leverages the same mass cytometry technology that has been the foundation to the success and world-wide adoption of the CyTOF Mass Cytometer. The technology enables comprehensive functional and phenotypic characterization of complex systems at the single cell level in diverse disciplines including immunology, cancer research, stem cell biology and drug profiling. On a newly designed chassis, the CyTOF 2 system delivers enhanced performance and improved user experience, providing the most powerful cell analysis platform on the market. The CyTOF 2 platform uniquely has the ability to simultaneously measure up to 120 cell biomarkers in single cells at up to 1000 cells per second. DVS Cytobank™, a cloud based analytical software platform, is also available to automatically analyze and manage data sets resulting from the CyTOF platform.

The new MaxPar Panel Kits deliver an integrated research solution for the CyTOF customer. The MaxPar Panel Kits contain all necessary reagents researchers need to carry out high dimensional experiments in a single tube. Five new MaxPar Panel Kits are now available that provide up to 17 ready to use metal-conjugated antibodies and can be combined simultaneously with up to 16 additional antibodies allowing high resolution single cell assays of multiple cell populations in a single tube.

“These new products place DVS Sciences at the cutting edge of life science research by providing the most comprehensive platform available to researchers for high parameter single cell analysis,” says Joseph Victor, President & CEO of DVS Sciences. “With these new products, DVS Sciences will continue to experience unprecedented world-wide growth allowing us to scale our customer support and provide additional resources to our new and existing customers,” Victor also commented.

For more information about the DVS Sciences CyTOF platform and MaxPar panels and reagents, please visit the DVS Sciences website at www.DVSsciences.com. Our new CyTOF 2 system will also be on display at booth #1530 at the AAI Immunology 2013™ conference in Honolulu, HI May 4 thru May 6.

About DVS Sciences, Inc.
DVS Sciences, Inc. manufactures and globally distributes novel bioanalytical solutions for use in biomarker discovery, biological research and potential future use in clinical applications. The patented multi-parameter technology comprises a high-throughput mass cytometer for quantitative individual cell analysis, CyTOF, and the MaxPar suite of stable isotope-tagged Panel Kits and reagents. The CyTOF platform overcomes the limitations of conventional flow cytometry, simplifies sample preparation, and has the capability to identify up to 120 biomarkers with high resolution and wide dynamic range. CyTOF systems are installed in leading laboratories across the U.S., Canada, Europe and Asia. DVS Sciences has its global headquarters and reagent kit manufacturing in Sunnyvale, California with a R&D and instrument manufacturing facility near Toronto, Canada and a sales/support office in the UK. DVS Sciences Instruments and Reagents are for Research Use Only, not for use in diagnostic procedures. The trademarks mentioned herein are the property of DVS Sciences Inc. or their respective owners.

DVS Sciences, Inc.
Nicole Ellis-Ovadia, +1 408-900-7224
Nicole.ovadia@dvssciences.com

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.